Skip to main content
. Author manuscript; available in PMC: 2022 Oct 7.
Published in final edited form as: J Thromb Haemost. 2021 Nov 21;20(1):32–38. doi: 10.1111/jth.15579

TABLE 1.

Suggested prophylactic regiments for patients on FXI(a) inhibitors requiring surgery

Low risk Moderate risk High risk
Observation or antifibrinolytic treatmenta,b Antifibrinolytic treatmenta,b Antifibrinolytic treatment and recombinant factor VIIaa,b
Cardiac catheterization Oral and ENT surgery Cardiac surgery
Cataract surgery Periodontal surgery Aortic aneurysm repair
PICC line placement Transurethral prostatectomy Pulmonary surgery
Fracture fixation Lithotripsy Mediastinoscopy
Carpal tunnel surgery Tonsillectomy Brain/CNS surgery
Endoscopy without biopsy Rhinoplasty Partial or total nephrectomy
Colonoscopy without biopsy Tooth extraction Colectomy
Skin biopsy Lymph node biopsy Total gastrectomy
Appendectomy Pacemaker insertion Pancreatectomy
Defibrillator insertion Thyroidectomy
Vagal nerve stimulation Cystectomy
Deep skin resection Facelift
Mastectomy Radical prostatectomy
Inguinal hernia repair Laparoscopic cholecystectomy
Ventral hernia repair Major neck surgery
Sleeve gastrectomy
Liposuction
Vitrectomy
Colonoscopy with biopsy
Hysterectomy with biopsy

Abbreviations: CNS, central nervous system; ENT, ear-nose-throat; PICC, peripherally inserted central catheter.

a

In situations in which surgery involves tissues with high fibrinolytic activity, administration of antifibrinolytic drugs may be extended to 10 days.

b

Doses of antifibrinolytic drugs may need to be adjusted in patients with reduced renal function.